Dario Neri
Papers
1
Total Citations
44
H-Index
1
About
Dario Neri is a pioneering figure in the field of antibody engineering and targeted cancer therapy. His research focuses on the development of innovative strategies for the selective delivery of therapeutic agents to solid tumors, with a particular emphasis on antibody-directed enzyme prodrug therapy (ADEPT) and the use of small immunoproteins. One of his most cited contributions is the engineering of a thermostable human prolyl endopeptidase for ADEPT, a groundbreaking approach that harnesses a post-proline cleaving endopeptidase to activate prodrugs specifically at the tumor site. This work, published in 2004 and garnering 44 citations, demonstrates his ability to combine protein engineering with clinical applications, creating a humanized enzyme that can be efficiently expressed in *E. coli* and purified for therapeutic use. Neri’s impact extends beyond this single paper; his broader body of work has significantly advanced the field of targeted therapeutics, with his research being widely cited and recognized for its translational potential. His achievements include the development of novel antibody formats and the exploration of cytokine-based therapies, solidifying his reputation as a leader in the quest for more precise and effective cancer treatments.
Research Focus
Key Achievements
Top Papers
- 1